Thursday, 24 April 2014

Novartis reports Q1 profit up on divestitures


Swiss pharmaceutical company Novartis AG has reported a 24 percent increase in profit for the first quarter, helped by selling off less-profitable parts of its business.


The Basel, Switzerland-based company says its net profit rose to nearly $2.97 billion, up from $2.42 billion in the period last year, driven by strong sales, key drug approvals and other factors such as growth in emerging markets, particularly China.


In a statement Thursday, the company attributed its quarterly profit to "higher operating income driven by the exceptional divestment gain and higher income from associated companies."


On Tuesday, Novartis launched a major overhaul of its business through a series of multibillion-dollar deals with Britain's GlaxoSmithKline PLC and Eli Lilly & Co. of the United States.



No comments:

Post a Comment